Crossmark

An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides

Crossref DOI link: https://doi.org/10.1186/s40425-018-0339-5

Published Online: 2018-04-17

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eggink, Laura L.

Roby, Katherine F.

Cote, Robert

Kenneth Hoober, J. https://orcid.org/0000-0003-0250-9970
Funding

Funding for this research was provided by:

Susavion Biosciences, Inc.
License Information

Text and Data Mining valid from 2018-04-17
More Information

Article History

Received: 20 February 2018

Accepted: 3 April 2018

First Online: 17 April 2018

Ethics approval and consent to participate

: Studies with commercially available human cells were conducted by Astarte Biologics, Inc., according to Institutional Review Board (IRB) approved protocols that are reviewed on an annual basis Studies with mice were conducted according to approved protocols by Biomodels LLC (IACUC approval number 13-0611-01) and at the University of Kansas Medical Center (IACUC approval number 2015-2288).

: Not applicable.

: LLE and JKH declare that they are inventors of the technology contained in this report. Intellectual property that has been assigned to Susavion Biosciences, Inc., in which these authors hold shares. Other authors have no conflicts of interest to report.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.